The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.7% between 2024 and 2031. The market size was estimated at $6.5 billion by 2022 and $11.8 billion by 2031.
The market for influenza vaccines is still expanding as a result of government-run immunization programs, rising awareness of the value of influenza prevention, and efficient vaccines. The COVID-19 pandemic highlighted the value of protecting against respiratory diseases and increased attention to influenza vaccination. The market is growing as a result of technological developments in vaccine manufacturing techniques and recombinant cell-based vaccinations.
Market Trend: Rising demand for quadrivalent flu vaccines due to broader protection against influenza strains
The influenza vaccine industry is undergoing a big transition towards quadrivalent vaccinations, which give protection against four influenza virus strains compared to previous trivalent vaccines protecting only three types This tendency is motivated by the demand for broad protection and widespread with seasonal influenza. Four-valent vaccines have been shown to be highly effective in preventing influenza-related hospitalizations and complications, and vaccines are being recommended by health care providers and government agencies four-valent protection of people has shown significantly, especially among vulnerable populations such as children and the elderly, leading to increased adoption rates worldwide . Vaccine producers are responding to this trend by extending their four-valent vaccinations and spending in research and development to improve and optimize the vaccine.
Market Driver: Increasing government initiatives and funding for influenza vaccination programs
Government support and infrastructure is critical to the growth of the influenza vaccine industry. Many countries have developed national vaccination programs that include influenza vaccine as part of routine immunization programs. These programs often provide free or reduced-cost vaccines to high-risk populations, such as children, the elderly, and the terminally ill Governments also fund them promote programs to educate the public about the benefits of influenza vaccination, and how it can help prevent seasonal infections. In addition, heavy investments in vaccine research and development led to the release of more robust and technologically advanced vaccines The COVID-19 pandemic highlighted the need for vaccination programs, prompting countries to invest heavily influenza vaccine as part of their comprehensive public health program
Market Restraint: Vaccine hesitancy and misconceptions about flu vaccines limiting market growth
Even if the influenza vaccination has shown clear advantages, delayed vaccination still poses a substantial obstacle to market expansion. Among some groups of people, there are still misunderstandings regarding the quality of protection given, its effectiveness, and possible negative consequences. Notwithstanding scientific data to the contrary, some people think flu vaccines might induce a cold or have major negative effects. This issue has been exacerbated by the dissemination of false information via various channels including social media. Furthermore aggravating vaccination is the belief that influenza is a benign disease not needing vaccine. Health care practitioners, public health groups, and vaccine producers working together will help to overcome these obstacles by educating the public and attending to issues. The difficulty goes beyond personal health of vaccine delay effects to include general efficiency of immunization campaigns and possible market expansion.
Quadrivalent Vaccines Segment Dominates the Market Quadrivalent vaccines offer broader protection against influenza strains, driving their adoption
Valent's four vaccine category has emerged as a major force in the influenza vaccination industry, commanding a sizable market share. This dominance may be attributable to the higher protection afforded by four-valent vaccinations, which target four distinct influenza viruses rather than the three viruses that vaccines have power to cover. the Health care practitioners and patients prefer four-valent vaccinations more because of larger coverage and probably higher efficacy in reducing influenza-related problems. Supported by recommendations from health authorities, with excellent clinical data demonstrating effectiveness, Vaccine producers have responded to this trend by extending their four-valent vaccine portfolios and increasing production capacity. The increased uptake of quadrivalent vaccinations is projected to fuel market expansion in the coming years.
North America Leads the Global Flu Vaccine Market High vaccination rates and strong healthcare infrastructure drive regional dominance
North America currently dominates the global influenza vaccine market, with the largest market share. This regional leadership comes from high vaccination rates, strong healthcare systems, and good government policies promoting influenza vaccination The region benefits from leading vaccine manufacturers and networks that widening distribution to ensure routine vaccine delivery and availability In addition, government policies and mandates such as vaccines required for health workers and schoolchildren help drive demand is strong. Well-established coverage and insurance coverage for glaucoma contributes significantly to the market growth in North America. The region’s advanced research and development also drives innovation in defense technologies, helping it maintain its market leadership position.
The influenza vaccine market is characterized by fierce competition between a few key players and several emerging companies. Established pharmaceutical giants such as Sanofi, GlaxoSmithKline and Sekiras (CSL Limited) dominate the market with their broad product range and global presence These companies constantly invest in research and development to make the vaccine take off effectiveness and improved methods. In recent years, biotechnology companies developing new vaccine technologies such as cell-based recombinant vaccines have increased competition The entry of new players and expanded manufacturing capacity has increased market competition. Collaborations and partnerships between vaccine manufacturers and research institutes are common, driving innovation in the field. The COVID-19 pandemic has further intensified competition, as companies use their vaccine development expertise to expand their influenza vaccine offerings. Price competition, especially in government tenders, is an important factor affecting market development.
Sanofi Pasteur
GlaxoSmithKline plc
Seqirus (CSL Limited)
AstraZeneca
Novavax, Inc.
Sinovac Biotech Ltd.
Pfizer Inc.
Biodiem
Emergent BioSolutions
Moderna, Inc.
Altimmune, Inc.
FluGen, Inc.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Flu Vaccine Market (2018 – 2022)
3.2. Global Flu Vaccine Market (2023 – 2031)
3.2.1. Market Segment By Type (2023 – 2031)
3.2.2. Market Segment By Technology (2023 – 2031)
3.2.3. Market Segment By Age Group (2023 – 2031)
3.2.4. Market Segment By Distribution Channel (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Rising demand for quadrivalent flu vaccines due to broader protection against influenza strains
4.1.2. Increasing adoption of cell-based and recombinant vaccine technologies
4.1.3. Growing focus on universal flu vaccines
4.2. Market Drivers
4.2.1. Increasing government initiatives and funding for influenza vaccination programs
4.2.2. Rising awareness about the importance of flu prevention
4.2.3. Technological advancements in vaccine production methods
4.3. Market Restraints
4.3.1. Vaccine hesitancy and misconceptions about flu vaccines limiting market growth
4.3.2. Challenges in predicting and matching circulating flu strains
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Quadrivalent
5.2. Trivalent
6. BY TECHNOLOGY
6.1. Egg-based
6.2. Cell-based
6.3. Recombinant
7. BY AGE GROUP
7.1. Pediatric
7.2. Adult
8. BY DISTRIBUTION CHANNEL
8.1. Hospital & Retail Pharmacies
8.2. Government Suppliers
8.3. Others
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. Sanofi Pasteur
12.2. GlaxoSmithKline plc
12.3. Seqirus (CSL Limited)
12.4. AstraZeneca
12.5. Novavax, Inc.
12.6. Sinovac Biotech Ltd.
12.7. Pfizer Inc.
12.8. Biodiem
12.9. Emergent BioSolutions
12.10. Moderna, Inc.
12.11. Altimmune, Inc.
12.12. FluGen, Inc. (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Type:
Quadrivalent
Trivalent
By Technology:
Egg-based
Cell-based
Recombinant
By Age Group:
Pediatric
Adult
By Distribution Channel:
Hospital & Retail Pharmacies
Government Suppliers
Others
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
